← Back to Search

[18F]-FTC-146 Imaging for Healthy Controls (rSIG Trial)

Phase 1
Waitlist Available
Led By Carolyn Rodriguez, MD, PhD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Capacity to provide informed consent
Ages 18-65
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 week
Awards & highlights

rSIG Trial Summary

This trial tests how well a new brain imaging agent works in healthy people.

Who is the study for?
This trial is for healthy individuals aged 18-65, capable of giving informed consent. Participants can be of any gender or ethnicity but must use effective birth control if female. Those with a history of psychiatric diagnoses, major medical or neurological issues, metal implants not suitable for MRI scans, or who are pregnant/nursing cannot join.Check my eligibility
What is being tested?
[18F]-FTC-146's reliability in brain uptake is being tested in this study. The goal is to understand how consistently the substance accumulates in the brains of healthy people without influencing factors like medication or existing health conditions.See study design
What are the potential side effects?
Since [18F]-FTC-146 is used as a diagnostic tool and participants are healthy controls, significant side effects are not anticipated. However, typical risks associated with PET imaging may include discomfort at the injection site and exposure to low levels of radiation.

rSIG Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I understand and can agree to the study's procedures and risks.
Select...
I am between 18 and 65 years old.

rSIG Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 week
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 week for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Reliability under test retest conditions

rSIG Trial Design

1Treatment groups
Experimental Treatment
Group I: [18F]-FTC-146Experimental Treatment1 Intervention
[18F]-FTC-146
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
[18F]-FTC-146
2016
Completed Early Phase 1
~30

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,386 Previous Clinical Trials
17,334,002 Total Patients Enrolled
Carolyn Rodriguez, MD, PhDPrincipal InvestigatorStanford University
5 Previous Clinical Trials
262 Total Patients Enrolled

Media Library

[18F]-FTC-146 Clinical Trial Eligibility Overview. Trial Name: NCT03649555 — Phase 1
Healthy Controls Research Study Groups: [18F]-FTC-146
Healthy Controls Clinical Trial 2023: [18F]-FTC-146 Highlights & Side Effects. Trial Name: NCT03649555 — Phase 1
[18F]-FTC-146 2023 Treatment Timeline for Medical Study. Trial Name: NCT03649555 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this experiment include participants of advanced age?

"Eligible participants must satisfy the following criteria: over 18 years of age and below 65."

Answered by AI

Who qualifies to partake in this scientific investigation?

"This study requires 6 volunteers aged between 18 and 65 with healthy controls. Applicants must also meet the following criteria: gender inclusive, ethnically diverse, capable of giving informed consent, and female participants will need to utilize a dependable contraceptive throughout the trial."

Answered by AI

Is this medical trial presently accepting participants?

"Clinicaltrials.gov states that this clinical trial is no longer recruiting for participants, though it was originally published on February 1st 2019 and last edited on June 15th 2022. Nevertheless, there are currently 9 other trials open to enrollment."

Answered by AI

Has the [18F]-FTC-146 drug acquired clearance from the Food and Drug Administration?

"Our team at Power assigned [18F]-FTC-146 a score of 1 on the safety scale due to its Phase 1 status and thus, lack of clinical data affirming its safety or efficacy."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Reliability of [18F]-FTC-146 Brain Uptake in Healthy Controls
Carolyn Rodriguez 2019. "Reliability of [18F]-FTC-146 Brain Uptake in Healthy Controls". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03649555.
~0 spots leftby Oct 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top